Verrica Partner Torii Pharma: Positive Top-line Results from Confirmatory Phase 3 Trial

 Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that its development and commercialization partner, Torii Pharmaceutical Co., Ltd. (“Torii”), reported positive top-line results from its Phase 3 trial of TO-208 (referred to as VP-102 and marketed as YCANTH™ in the U.S.) for the treatment of Molluscum Contagiosum (“molluscum”) in Japan.

The Phase 3 trial was conducted in Japan and is a double blind, randomized and parallel-group comparison study to evaluate the efficacy and safety of TO-208 in comparison to placebo, when applied once every 21 days for up to four applications in patients with molluscum. The top-line results show that the proportion of subjects achieving complete clearance of all treatable molluscum lesions at the completion of the confirmatory study, the primary endpoint of efficacy, was statistically significant versus placebo. TO-208 was well tolerated during the study.

https://www.globenewswire.com/news-release/2023/12/15/2796913/0/en/Verrica-Pharmaceuticals-Development-and-Commercialization-Partner-Torii-Pharmaceutical-Co-Ltd-Announces-Positive-Top-line-Results-from-a-Confirmatory-Phase-3-Trial-of-TO-208-for-th.html